Table 1.
Characteristics of sample.
| Total subjects | Approach 1 FACT-F 43 cut-off |
Approach 2 FACT-F 3-point change |
Approach 3 PROMIS T-score >50 cut-off |
||||
|---|---|---|---|---|---|---|---|
| N = 43 | CF (n=13) | NF (n=21) | CF (n=10) | NF (n=19) | CF (n=12) | NF (n=23) | |
|
| |||||||
| Age | 66.1±1.2 | 63.6 ±2.3 | 66.1±1.6 | 65.7±2.4 | 67.0±1.6 | 62.5±2.4 | 66.2±1.5 |
| Race/Ethnicity | |||||||
| Caucasian | 62.5% | 76.9% | 66.7% | 70% | 78.9% | 66.7% | 69.6% |
| African American | 25% | 15.4% | 23.8% | 20% | 15.8% | 25% | 21.7% |
| Asian | 5.4% | 0% | 9.5% | 0% | 5.3% | 0% | 9.5% |
| Hispanic | 7.1% | 9.1% | 0% | 11.1% | 0% | 20% | 0% |
| Height (cm) | 175.6±1.1 | 176.4 ±1.8 | 175.8 ±1.5 | 175.2 ±1.7 | 175.0±1.6 | 176.7 ±2.2 | 176.5 ±1.5 |
| Weight (kg) | 92.4±2.2 | 94.4 ±4.2 | 90.4±3.1 | 96.6±4.2 | 88.2±3.2 | 93.3±4.1 | 91.9±3.1 |
| Body Mass Index | 30.1±0.7 | 30.8±1.5 | 29.2±0.9 | 32.0±1.8 | 28.8±1.0 | 30.4±1.5 | 29.4±0.9 |
| Albumin (g/dL) | 4.0±0.05 | 4.2±0.1 | 4.0±0.06 | 4.1±0.08 | 4.1±0.07 | 4.2±0.09 | 4.1±0.06 |
| Gleason Score | 7.8±0.1 | 7.±0.2 | 7.7±0.2 | 8.0±0.3 | 7.5±0.2 | 7.9±0.2 | 7.6±0.2 |
| Clinical T Stage | T1c – T3b | T1c – T3b | T1c – T3b | T1c – T3b | T1c – T3a | T1c – T3b | T1c – T3b |
| Karnofsky Performance Scale | 89.8±0.2 | 90.0±0.0 | 89.5±0.5 | 90.0±0.0 | 89.4±0.6 | 90.0±0.0 | 89.6±0.4 |
| PSA at baseline | 20.6±4.0 | 10.3±7.9 | 5.6±1.4 | 11.9±10.4 | 6.6±1.5 | 11.0±8.2 | 5.3±1.3 |
| PSA one year after EBRT | 0.2±0.1 | 0.05±0.01 | 0.2±0.2 | 0.05±0.01 | 0.2±0.2 | 0.05±0.01 | 0.2±0.1 |
FACT-F: Functional Assessment of Cancer Therapy – Fatigue; PROMIS: Patient Reported Outcomes Measurement Information System – Fatigue; cm: centimeter; kg: kilogram; g/dL: gram per deciliter; PSA: prostate specific antigen (ng/mL); EBRT: external beam radiation therapy; CF: chronic fatigue; NF: non-fatigued. Values are mean ± standard error.